LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature. It also provides carotid shunts that temporarily shunt the blood to the brain during the removal of plaque from the carotid artery in a carotid endarterectomy surgery; powered phlebectomy devices to remove varicose veins; and radiopaque tape, a medical-grade tape applied to the skin that enables interventionists to cross-refer between the inside and the outside of a patient's body, and allows them to locate tributaries or lesions beneath the skin. In addition, the company offers remote endarterectomy devices to remove plaque from arteries in the leg; valvulotomes that cuts valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and vascular grafts to bypass or replace diseased arteries. Further, it provides vascular patches, which are used for closure of vessels after surgical intervention, as well as endarterectomy and other vascular reconstruction; vessel closure systems to attach vessels to one another with titanium clips instead of sutures; and Reddick cholangiogram catheters to inject dye into the cystic duct during laparoscopic cholecystectomy, as well as laparoscopic accessory for use in laparoscopic gall bladder removal. LeMaitre Vascular, Inc. markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was founded in 1983 and is headquartered in Burlington, Massachusetts.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone781-221-2266
Debt
Current Ratio5.93
Quick Ratio4.30
Price-To-Earnings
Sales & Book Value
Annual Sales$100.87 million
Price / Sales4.54
Price / Cash Flow20.58
Price / Book4.11
Profitability
Net Income$17.17 million
Net Margins20.52%
Return on Assets15.79%
Miscellaneous
Employees423
OptionableOptionable
LeMaitre Vascular (NASDAQ:LMAT) Frequently Asked Questions
What is LeMaitre Vascular's stock symbol?
LeMaitre Vascular trades on the NASDAQ under the ticker symbol "LMAT."
How often does LeMaitre Vascular pay dividends? What is the dividend yield for LeMaitre Vascular?
LeMaitre Vascular announced a quarterly dividend on Monday, October 8th. Investors of record on Tuesday, November 20th will be given a dividend of $0.07 per share on Thursday, December 6th. This represents a $0.28 annualized dividend and a yield of 1.20%. The ex-dividend date is Monday, November 19th. View LeMaitre Vascular's Dividend History.
How will LeMaitre Vascular's stock buyback program work?
LeMaitre Vascular announced that its Board of Directors has authorized a stock buyback program on Friday, July 28th 2017, which authorizes the company to repurchase $7,500,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to repurchase up to 1.4% of its shares through open market purchases. Shares repurchase programs are often an indication that the company's board believes its stock is undervalued.
How were LeMaitre Vascular's earnings last quarter?
LeMaitre Vascular Inc (NASDAQ:LMAT) released its quarterly earnings results on Friday, October, 5th. The medical instruments supplier reported $0.21 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.21 by $0.00. The medical instruments supplier had revenue of $24.17 million for the quarter, compared to the consensus estimate of $26.06 million. LeMaitre Vascular had a net margin of 20.52% and a return on equity of 18.07%. View LeMaitre Vascular's Earnings History.
When is LeMaitre Vascular's next earnings date?
What price target have analysts set for LMAT?
6 Wall Street analysts have issued twelve-month price targets for LeMaitre Vascular's stock. Their forecasts range from $32.00 to $45.00. On average, they expect LeMaitre Vascular's stock price to reach $36.50 in the next year. This suggests a possible upside of 55.9% from the stock's current price. View Analyst Price Targets for LeMaitre Vascular.
What is the consensus analysts' recommendation for LeMaitre Vascular?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for LeMaitre Vascular in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for LeMaitre Vascular.
What are Wall Street analysts saying about LeMaitre Vascular stock?
Here are some recent quotes from research analysts about LeMaitre Vascular stock:
- 1. According to Zacks Investment Research, "LeMaitre Vascular, Inc. is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects the people worldwide. LeMaitre develops, manufactures, and markets disposable and implantable vascular devices to address the needs of vascular surgeons and interventionalists. LeMaitre's diversified product portfolio consists of twelve well-known brand name products used in arteries and veins outside of the heart and are supported by a growing, specialized and highly trained organization of vascular sales professionals. LeMaitre Vascular offers a wide range of innovative products to vascular surgeons and interventionalists for improving procedure efficacy and minimizing patient recovery time. " (12/6/2018)
- 2. Barrington Research analysts commented, "We are upgrading our investment rating on LMAT shares to OUTPERFORM (from MARKET PERFORM previously). We think that Friday’s trading action that resulted in a 20.7% downdraft in LMAT’s market value was overdone and provides investors with an attractive entry point. We have always liked this business and its leadership but had found stock valuation a recurring challenge when assessing this idea – until Friday, that is. Our price target is $34. We arrive at our target by attaching a 20x multiple to our 2019 adjusted EBITDA estimate. We assume approximately $60 million in net cash 12 months from now." (10/8/2018)
Has LeMaitre Vascular been receiving favorable news coverage?
Press coverage about LMAT stock has trended negative this week, according to InfoTrie Sentiment. InfoTrie scores the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. LeMaitre Vascular earned a media sentiment score of -2.5 on InfoTrie's scale. They also assigned headlines about the medical instruments supplier a news buzz of 2.0 out of 10, indicating that recent news coverage is very unlikely to have an effect on the company's share price in the immediate future.
Who are some of LeMaitre Vascular's key competitors?
Some companies that are related to LeMaitre Vascular include Mazor Robotics (MZOR), Atrion (ATRI), K2M Group (KTWO), Nevro (NVRO), AtriCure (ATRC), Tactile Systems Technology (TCMD), Luminex (LMNX), Cryolife (CRY), Cardiovascular Systems (CSII), Orthofix Medical (OFIX), Intersect ENT (XENT), AngioDynamics (ANGO), Cerus (CERS), OraSure Technologies (OSUR) and SurModics (SRDX).
Who are LeMaitre Vascular's key executives?
LeMaitre Vascular's management team includes the folowing people:
- Mr. George W. LeMaitre, Chairman & CEO (Age 54)
- Mr. David B. Roberts, Pres & Director (Age 55)
- Mr. Joseph P. Pellegrino Jr., CFO, Treasurer, Sec. & Director (Age 54)
- Mr. Trent G. Kamke, Sr. VP of Operations (Age 48)
- Dr. George D. LeMaitre, Founder and Chairman of Scientific Advisory Board (Age 85)
Who are LeMaitre Vascular's major shareholders?
LeMaitre Vascular's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Summit Creek Advisors LLC (1.72%) and Curbstone Financial Management Corp (0.09%). Company insiders that own LeMaitre Vascular stock include David B Roberts, George W Lemaitre, Joseph P Pellegrino Jr, Lawrence J Jasinski, Michael H Thomas, Michael T Wijas, Peter R Gebauer and Trent G Kamke. View Institutional Ownership Trends for LeMaitre Vascular.
Which institutional investors are selling LeMaitre Vascular stock?
LMAT stock was sold by a variety of institutional investors in the last quarter, including Curbstone Financial Management Corp. Company insiders that have sold LeMaitre Vascular company stock in the last year include David B Roberts, George W Lemaitre, Joseph P Pellegrino Jr, Michael H Thomas and Trent G Kamke. View Insider Buying and Selling for LeMaitre Vascular.
Which institutional investors are buying LeMaitre Vascular stock?
How do I buy shares of LeMaitre Vascular?
Shares of LMAT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is LeMaitre Vascular's stock price today?
One share of LMAT stock can currently be purchased for approximately $23.41.
How big of a company is LeMaitre Vascular?
LeMaitre Vascular has a market capitalization of $444.12 million and generates $100.87 million in revenue each year. The medical instruments supplier earns $17.17 million in net income (profit) each year or $0.86 on an earnings per share basis. LeMaitre Vascular employs 423 workers across the globe.
What is LeMaitre Vascular's official website?
How can I contact LeMaitre Vascular?
LeMaitre Vascular's mailing address is 63 SECOND AVENUE, BURLINGTON MA, 01803. The medical instruments supplier can be reached via phone at 781-221-2266.
MarketBeat Community Rating for LeMaitre Vascular (NASDAQ LMAT)
MarketBeat's community ratings are surveys of what our community members think about LeMaitre Vascular and other stocks. Vote "Outperform" if you believe LMAT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LMAT will underperform the S&P 500 over the long term. You may vote once every thirty days.
